MY200791A - Composition for controlled ovarian stimulation - Google Patents

Composition for controlled ovarian stimulation

Info

Publication number
MY200791A
MY200791A MYPI2020000971A MYPI2020000971A MY200791A MY 200791 A MY200791 A MY 200791A MY PI2020000971 A MYPI2020000971 A MY PI2020000971A MY PI2020000971 A MYPI2020000971 A MY PI2020000971A MY 200791 A MY200791 A MY 200791A
Authority
MY
Malaysia
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
fsh
Prior art date
Application number
MYPI2020000971A
Other languages
English (en)
Inventor
Bjarke Mirner Klein
Lisbeth Helmgaard
Saez Joan-Carles Arce
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MY200791A publication Critical patent/MY200791A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2020000971A 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation MY200791A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (1)

Publication Number Publication Date
MY200791A true MY200791A (en) 2024-01-16

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020000971A MY200791A (en) 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation

Country Status (32)

Country Link
US (2) US11744879B2 (enExample)
EP (3) EP3973982B1 (enExample)
JP (2) JP6856819B2 (enExample)
KR (2) KR20250078595A (enExample)
CN (2) CN120617484A (enExample)
AR (1) AR112541A1 (enExample)
AU (1) AU2018326556B2 (enExample)
BR (1) BR112020003379A2 (enExample)
CA (1) CA3073624A1 (enExample)
CL (1) CL2020000482A1 (enExample)
DK (2) DK3675894T3 (enExample)
EA (1) EA202090480A1 (enExample)
ES (2) ES2904787T3 (enExample)
FI (1) FI3973982T3 (enExample)
HR (2) HRP20211802T1 (enExample)
HU (2) HUE068024T2 (enExample)
IL (1) IL272763B2 (enExample)
JO (1) JOP20200034A1 (enExample)
LT (2) LT3973982T (enExample)
MA (2) MA50034B1 (enExample)
MD (2) MD3973982T2 (enExample)
MX (2) MX2020002235A (enExample)
MY (1) MY200791A (enExample)
PH (1) PH12020500404A1 (enExample)
PL (2) PL3973982T3 (enExample)
PT (2) PT3675894T (enExample)
RS (2) RS62810B1 (enExample)
SG (1) SG11202003840QA (enExample)
SI (2) SI3973982T1 (enExample)
TW (1) TWI749255B (enExample)
UA (1) UA126869C2 (enExample)
WO (1) WO2019043143A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267608T1 (de) * 2000-01-27 2004-06-15 Applied Research Systems Verwendung von fsh zur behandlung von infertilität
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (en) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CA2945883A1 (en) * 2014-04-18 2015-10-22 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
MD3261661T2 (ro) 2015-02-26 2024-04-30 Ferring Bv Menotropină pentru tratarea infertilității
HUE048757T2 (hu) * 2015-04-17 2020-08-28 Ferring Bv FSH meddõség kezelésére
EP3286209B1 (en) 2015-04-24 2020-11-25 Ferring BV Method of production of gonadotrophin
AU2016282916B2 (en) 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
US20240024424A1 (en) 2024-01-25
IL272763B2 (en) 2024-02-01
CN111050787A (zh) 2020-04-21
PL3973982T3 (pl) 2024-11-04
AR112541A1 (es) 2019-11-06
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
EP4427806A2 (en) 2024-09-11
SG11202003840QA (en) 2020-05-28
RS65945B1 (sr) 2024-10-31
UA126869C2 (uk) 2023-02-15
FI3973982T3 (fi) 2024-09-23
CN120617484A (zh) 2025-09-12
JP2021046398A (ja) 2021-03-25
KR20250078595A (ko) 2025-06-02
HRP20211802T1 (hr) 2022-03-04
HUE056726T2 (hu) 2022-03-28
DK3973982T3 (da) 2024-09-23
HUE068024T2 (hu) 2024-12-28
SI3973982T1 (sl) 2024-10-30
MA56224B1 (fr) 2024-09-30
MX2024009224A (es) 2024-08-06
PT3675894T (pt) 2022-01-25
MA50034B1 (fr) 2022-02-28
PT3973982T (pt) 2024-09-16
MA50034A (fr) 2021-05-12
LT3973982T (lt) 2024-09-10
BR112020003379A2 (pt) 2020-08-25
SI3675894T1 (sl) 2022-01-31
EP4427806A3 (en) 2024-10-09
IL272763A (en) 2020-04-30
ES2989511T3 (es) 2024-11-26
TWI749255B (zh) 2021-12-11
CL2020000482A1 (es) 2020-06-26
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
EP3973982A1 (en) 2022-03-30
US20200197493A1 (en) 2020-06-25
US11744879B2 (en) 2023-09-05
EP3973982B1 (en) 2024-07-31
WO2019043143A1 (en) 2019-03-07
JP2020528071A (ja) 2020-09-17
MD3973982T2 (ro) 2024-11-30
AU2018326556A1 (en) 2020-03-05
MX2020002235A (es) 2020-07-20
AU2018326556B2 (en) 2024-09-26
TW201919687A (zh) 2019-06-01
PH12020500404A1 (en) 2021-03-01
MA56224A (fr) 2022-04-20
JP7373479B2 (ja) 2023-11-02
ES2904787T3 (es) 2022-04-06
KR20200045543A (ko) 2020-05-04
EP3675894B1 (en) 2021-11-03
EP3675894A1 (en) 2020-07-08
MD3675894T2 (ro) 2022-03-31
CA3073624A1 (en) 2019-03-07
JOP20200034A1 (ar) 2020-02-13
HRP20241171T1 (hr) 2024-11-22
DK3675894T3 (da) 2022-01-24
RS62810B1 (sr) 2022-02-28
JP6856819B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
EP4218785A3 (en) Mitochondria-targeting peptides
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MX2018016257A (es) Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
PH12020550340A1 (en) Anti-pacap antibody
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
EP4534145A3 (en) Composition for controlled ovarian stimulation
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2018189661A3 (en) Methods and compounds for treating diabetes
MX2020000402A (es) Nuevos derivados de xantina sustituidos.
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
PH12020500404A1 (en) Composition for controlled ovarian stimulation
MX2018002921A (es) Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2020011738A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
WO2019079698A8 (en) Tissue products with variations in mechanical properties and methods of treatment
MA53909B1 (fr) Compositions et méthodes de stimulation ovarienne contrôlée
MY199547A (en) Phosphaplatin liquid formulations
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.